Global Non-alcoholic Steatohepatitis (NASH) Treatment Market to Grow at a CAGR of 5.7% During the Period 2024-2032, Driven by Rising Number of Cases of NAFLD and NASH

Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver disease (NAFLD). It is indicated by excessive accumulation of fat in the liver, inflammation, cell injury and fibrosis. Non-alcoholic fatty liver disease (NAFLD) is a significant cause of liver disease across the world. The global prevalence of NAFLD is estimated to be over 25% with maximum prevalence in the Middle East and South America, and lowermost in Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Developments

In 2021, advances in non-alcoholic fatty liver disease were revealed at the International Liver Congress in Geneva, Switzerland. A key development discussed at the meeting was a study that showed noninvasively identified non-alcoholic steatohepatitis (NASH) patients treated with 100 mg per day of resmetirom for up to fifty-two weeks exhibited rapid and sustained reduction in fibrosis stage, hepatic fat, LDL and atherogenic lipids, inflammatory biomarkers and liver enzymes. Such developments are expected to boost the global non-alcoholic steatohepatitis (NASH) treatment market.

In 2021, Akero announced positive histological improvements in cirrhotic NASH (F4) patients after sixteen weeks in Extension Cohort C. 33% of patients treated with efruxifermin (EFX) (4 of 12) showed improvement by one fibrosis stage without deterioration of NASH. 25% of EFX patients (3 of 12) exhibited NASH resolution. Rapid fibrosis improvement in cirrhotic patients was observed after only 16 weeks of EFX treatment, the highest rate reported publicly to date, suggested direct anti-fibrotic effects.

In 2019, Gilead presented new data on non-alcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019 in Vienna. The data supported Gilead’s efforts to develop combination therapies to target different aspects of NASH, assess the utility of non-invasive tests for the recognition of patients living with the disease and advance overall understanding of the complexities and burden of NASH. Such developments are expected to boost the global non-alcoholic steatohepatitis (NASH) treatment market.

In 2020, LG Chem announced that it had received approval for NASH treatment for Clinical Phase 1 Trial by the USA FDA. The approval was to conduct clinical trials for candidate material with mechanism for suppressing liver inflammations based on outstanding pre-clinical results. LG Chem would begin clinical development for new NASH drugs in the USA.

In 2018, Novartis announced that it had entered into a clinical development agreement with Pfizer which would include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).

In 2021, Boehringer Ingelheim and Zealand Pharma A/S announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH).

In 2022, Intercept Pharmaceuticals, Inc. announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due to non-alcoholic steatohepatitis (NASH).

Key Findings of the Report

• The global non-alcoholic steatohepatitis (NASH) treatment market is expected to be driven by rising number of cases of NAFLD and NASH.

• Developments in research and medicine are likely to stimulate market growth.

• North America, South America, Europe and Middle East are projected to be key markets.

Market Analysis by Drug Type, Disease Cause, End Use and Region

• By drug type, the market is segmented into Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cencicriviroc, and Others.

• By disease cause, the market is divided into Hypertension, Heart Disease, High Blood Lipid, Type 2 diabetes, Obesity, and Others.

• By end use, the market is classified into Hospitals, Clinics, and Homecare Settings.

• By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.